The impact of the AMPD1 gene polymorphism on exercise capacity, other prognostic parameters, and survival in patients with stable congestive heart failure. A study on 686 consecutive patients.

[1]  J. E. Hansen,et al.  Predicted values for clinical exercise testing. , 2015, The American review of respiratory disease.

[2]  V. Cameron,et al.  Evaluation of AMPD1 C34T genotype as a predictor of mortality in heart failure and post-myocardial infarction patients. , 2006, American heart journal.

[3]  B. Horne,et al.  The role of a common adenosine monophosphate deaminase (AMPD)-1 polymorphism in outcomes of ischemic and nonischemic heart failure. , 2005, Journal of cardiac failure.

[4]  P. Amouyel,et al.  The impact of beta‐adrenoreceptor gene polymorphisms on survival in patients with congestive heart failure * , 2005, European journal of heart failure.

[5]  A. Lucia,et al.  Frequency of the C34T mutation of the AMPD1 gene in world-class endurance athletes: does this mutation impair performance? , 2005, Journal of applied physiology.

[6]  B. Horne,et al.  A common variant of the AMPD1 gene predicts improved survival in patients with ischemic left ventricular dysfunction. , 2004, Journal of cardiac failure.

[7]  D. Reinhardt,et al.  Role of adenosine monophosphate deaminase-1 gene polymorphism in patients with congestive heart failure (influence on tumor necrosis factor-alpha level and outcome). , 2004, The American journal of cardiology.

[8]  N. Lamblin,et al.  B-type natriuretic peptide and peak exercise oxygen consumption provide independent information for risk stratification in patients with stable congestive heart failure. , 2004, Journal of the American College of Cardiology.

[9]  E. Picano,et al.  AMPD1 (C34T) polymorphism and clinical outcomes in patients undergoing myocardial revascularization. , 2004, International journal of cardiology.

[10]  M. Komajda,et al.  Combination of B-type natriuretic peptide and peak oxygen consumption improves risk stratification in outpatients with chronic heart failure. , 2003, American heart journal.

[11]  M. Yacoub,et al.  Decreased cardiac activity of AMP deaminase in subjects with the AMPD1 mutation--a potential mechanism of protection in heart failure. , 2003, Cardiovascular research.

[12]  S. Ball,et al.  An evaluation of the beta‐1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT‐HF sub‐study , 2003, European journal of heart failure.

[13]  C. Bouchard,et al.  Associations between cardiorespiratory responses to exercise and the C34T AMPD1 gene polymorphism in the HERITAGE Family Study. , 2003, Physiological genomics.

[14]  Piero Zardini,et al.  Determinants and prognostic value of left atrial volume in patients with dilated cardiomyopathy. , 2002, Journal of the American College of Cardiology.

[15]  R. Sabina,et al.  Regulation of skeletal muscle ATP catabolism by AMPD1 genotype during sprint exercise in asymptomatic subjects. , 2001, Journal of applied physiology.

[16]  J. W. Rush,et al.  Myoadenylate deaminase deficiency does not affect muscle anaplerosis during exhaustive exercise in humans , 2001, The Journal of physiology.

[17]  B. Horne,et al.  A common variant of the AMPD1 gene predicts improved cardiovascular survival in patients with coronary artery disease. , 2000, Journal of the American College of Cardiology.

[18]  T. Rebbeck,et al.  Common variant in AMPD1 gene predicts improved clinical outcome in patients with heart failure. , 1999, Circulation.

[19]  R. Sabina,et al.  Genetic and other determinants of AMP deaminase activity in healthy adult skeletal muscle. , 1998, Journal of applied physiology.

[20]  X Marchandise,et al.  Right ventricular ejection fraction is an independent predictor of survival in patients with moderate heart failure. , 1998, Journal of the American College of Cardiology.

[21]  E. Jansson,et al.  Muscle amp deaminase deficiency in 2% of a healthy population , 1995, Muscle & nerve.

[22]  T. Morisaki,et al.  Molecular basis of AMP deaminase deficiency in skeletal muscle. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[23]  T. Morisaki,et al.  Adenylate deaminase. A multigene family in humans and rats. , 1990, The Journal of biological chemistry.

[24]  B. Hamel,et al.  Myoadenylate deaminase deficiency: A clinical, genetic, and biochemical study in nine families , 1988, Muscle & nerve.

[25]  Shirley A. Miller,et al.  A simple salting out procedure for extracting DNA from human nucleated cells. , 1988, Nucleic acids research.

[26]  S. Dimauro,et al.  Familial myoadenylate deaminase deficiency and exertional myalgia , 1982, Neurology.

[27]  W. Fishbein,et al.  Myoadenylate deaminase deficiency: a new disease of muscle. , 1978, Science.